Trending
All Articles
The most effective method to Shake Hands During a Pandemic: Wellbeing Tips and Behavior19.10.2023Amidst a worldwide pandemic, customary handshakes have gone under investigation because of wellbeing concerns. In any case, ton this
Asia's migrant workers debate if Gulf jobs are worth deadly risk of Iran war31.03.2026Iran's strikes on Gulf states have been especially hard for migrants who have long supported these economies to lift their families back home from poverty.
Top 10 Arising Advances That Will Shape What's in store11.08.2023Headways in innovation are continually reshaping our reality, prompting extraordinary changes in different businesses and parts of life. As
The race to mine the moon is on – and it urgently needs some clear international rules31.12.2025There are billions of dollars in it for companies able to kickstart mining operations, even if such returns are still years away.
7 Countries Where Newcomers Feel Most Welcome, and 3 Where They Often Don’t05.04.2026InterNations’ 2025 survey suggests Mexico, Panama, Colombia, Indonesia, the Philippines, Brazil, and Oman feel especially welcoming to foreign residents, while Kuwait, Norway, and Finland come across as much harder places to socially settle into.
10 Activities to Lift Your Consume and Bust Your Stomach05.06.2024Consuming fat doesn't need to be a dull or tiresome cycle. Integrating fun and connecting with practices into your routine can
Flu concerns grow in US as UK sees more cases among kids08.12.2025Some U.S. hospitals are starting to put seasonal visitor restrictions in place.
Novo Nordisk justifies reasoning behind failed GLP-1 Alzheimer's trials02.12.2025SAN DIEGO Dec 2 (Reuters) - Novo Nordisk in 2020 launched pivotal trials of its GLP-1 drug semaglutide in Alzheimer's patients based on studies in humans, animals and real-world findings, a top company executive said on Tuesday, acknowledging criticism that Novo's studies had design flaws. Although the trials failed to show statistically significant slowing of cognitive decline in patients given the drug, "we still think it was the right decision.





















